View allCompanies IntelligenceAstellas Pharma IncI & A, INC.SNDAAstellas B.V.View all
The regulator has set 9 December 2023 as the Prescription Drug User Fee Act goal date for the review of Astellas’ sNDA.
The sNDA is based on results from a Phase II open-label, multicentre, non-comparative study that evaluated the tolerability, safety, efficacy and pharmacokinetics of CRESEMBA.
Astellas’ study enrolled 31 participants aged from one to 17 years diagnosed with IA or IM.
Participants received a loading dose of CRESEMBA intravenously or at the investigator’s discretion, and an oral dose every eight hours on days one and two.
They were then followed while receiving a once-daily maintenance dose.
Astellas US Medical Specialties business unit head and senior vice-president Lynn Fenicchia stated: “Since its approval over eight years ago, CRESEMBA has been helping adult patients and their physicians fight certain life-threatening fungal infections when they are often critically ill with other diseases.
“This sNDA acceptance by the FDA brings Astellas one step closer to helping paediatric patients by potentially having a new treatment option available for IA and IM for a younger patient population if approved.”
The most frequently reported adverse reactions among CRESEMBA-treated patients included nausea (26%), vomiting (25%), diarrhoea (22%), headache (17%) and elevated liver chemistry tests (16%).
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.